Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation
Sign Up to like & getrecommendations! Published in 2021 at "Hepatology International"
DOI: 10.1007/s12072-021-10159-w
Abstract: The study investigated the role of hepatitis B core-related antigen (HBcrAg) in hepatitis B virus (HBV) relapse after stopping tenofovir disoproxil fumarate (TDF) in HBeAg-negative patients. A total of 185 HBeAg-negative patients without cirrhosis who… read more here.
Keywords: hepatitis; treatment; hbv relapse; relapse ... See more keywords